Ideaya Biosciences Inc. (IDYA)
IDEAYA Biosciences Spotlights Darovasertib Win, FDA Review Path at Oncology Summit
IDEAYA Biosciences NASDAQ: IDYA executives highlighted recent clinical progress across the company's oncology pipeline during a fireside chat at TD Cowen's seventh annual Oncology Innovation Summit, with the discussion focused primarily on darovasertib combinations in uveal melanoma and several earlier-stage antibody-drug conjugate and synthetic lethality programs.
IDEAYA Biosciences Eyes Busy 2026 as Darovasertib Advances Toward FDA Filing
IDEAYA Biosciences NASDAQ: IDYA Chief Executive Yujiro Hata said the precision oncology company is preparing for a busy 2026, led by regulatory and clinical milestones for darovasertib in metastatic uveal melanoma and multiple data readouts across its pipeline.
IDEAYA Biosciences, Inc. (IDYA) Presents at Bank of America Global Healthcare Conference 2026 Transcript
IDEAYA Biosciences, Inc. (IDYA) Presents at Bank of America Global Healthcare Conference 2026 Transcript
IDEAYA Biosciences, Inc. (IDYA) Reports Q1 Loss, Misses Revenue Estimates
IDEAYA Biosciences, Inc. (IDYA) came out with a quarterly loss of $1.11 per share versus the Zacks Consensus Estimate of a loss of $1.07. This compares to a loss of $0.82 per share a year ago.
IDEAYA Biosciences, Inc. (IDYA) Discusses Topline Results from OptimUM-02 Trial Evaluating Darovasertib and Crizotinib in HLA-A2-Negative Metastatic Uveal Melanoma Transcript
IDEAYA Biosciences, Inc. (IDYA) Discusses Topline Results from OptimUM-02 Trial Evaluating Darovasertib and Crizotinib in HLA-A2-Negative Metastatic Uveal Melanoma Transcript
Ideaya Biosciences: Key Pivotal Data Imminent
Ideaya Biosciences is on the verge of a pivotal data readout for darovasertib, its lead uveal melanoma candidate. IDYA maintains a strong cash runway of 3–4 years, supporting a robust and expanding pipeline targeting multiple high-value oncology indications. Darovasertib has shown promising efficacy as both monotherapy and in combination, with phase 3 data expected imminently and potential for FDA approval.
IDEAYA Biosciences, Inc. (IDYA) Discusses Pipeline Progress and Upcoming Data Readout in Uveal Melanoma and ADC Programs Transcript
IDEAYA Biosciences, Inc. (IDYA) Discusses Pipeline Progress and Upcoming Data Readout in Uveal Melanoma and ADC Programs Transcript
IDEAYA Biosciences, Inc. (IDYA) Presents at Citi's 2026 Virtual Oncology Leadership Summit Transcript
IDEAYA Biosciences, Inc. (IDYA) Presents at Citi's 2026 Virtual Oncology Leadership Summit Transcript
IDEAYA Biosciences, Inc. (IDYA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
IDEAYA Biosciences, Inc. (IDYA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
IDEAYA Biosciences, Inc. (IDYA) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
IDEAYA Biosciences, Inc. (IDYA) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Ideaya Biosciences: Primed For Success - Major Eye Cancer Catalyst Weeks Away
Ideaya Biosciences, Inc. is a precision oncology company with a robust pipeline, highlighted by lead asset darovasertib for uveal melanoma. IDYA's darovasertib shows promising Phase 2 results and multiple pivotal studies, with a potential $500M+ peak revenue opportunity and a strong partnership with Servier. The pipeline includes collaborations with major pharma and several near-term catalysts, suggesting IDYA's current $3.1B valuation undervalues its broader portfolio.
IDEAYA Biosciences, Inc. (IDYA) Presents at Citi's 2025 SMID Cap Biopharma Call Series Transcript
IDEAYA Biosciences, Inc. ( IDYA ) Citi's 2025 SMID Cap Biopharma Call Series November 6, 2025 12:00 PM EST Company Participants Yujiro Hata - Founder, President, CEO & Director Conference Call Participants Yigal Nochomovitz - Citigroup Inc., Research Division Presentation Yigal Nochomovitz Citigroup Inc., Research Division All right. Great. Hopefully, everyone is connected.
